|
Acanthosis Nigricans
|
0.010 |
Biomarker
|
disease |
BEFREE |
Indirect evidence suggests a role for tyrosine kinase growth factor receptor signalling in the pathogenesis of AN.
|
12452857 |
2002 |
|
Actinic cheilitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
VEGFR1 expression in epithelial and inflammatory cells and VEGFR2 expression in epithelial cells were higher in AC compared to LLSCC (p < 0.05).
|
25895461 |
2015 |
|
Acute Cerebrovascular Accidents
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fluorescence-activated cell sorting (FACS) revealed higher levels of circulating CD133+/CD34+/KDR+/CD45+ cells in the acute strokes as compared to the control subjects (p=0.02).
|
20594997 |
2010 |
|
Acute Chest Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Short-term dual antiplatelet therapy in ACS patients restores the low platelet/KDR<sup>+</sup> conjugates and CD34<sup>+</sup> cell levels and improves the low membrane expression levels of KDR in these cells, an effect being more pronounced in ticagrelor-treated patients.
|
29451832 |
2019 |
|
Acute Coronary Syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Modern theories of acute coronary syndrome mainly focus on rupture of thin-cap fibroatheromas (TCFAs), which is closely related to the release of vascular endothelial growth factor and its receptor (VEGF/VEGFR).
|
29551453 |
2018 |
|
Acute Coronary Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In patients from a prospectively recruited post-acute coronary syndromes cohort we investigated the prognostic performance of three products of activated macrophages, soluble vascular endothelial growth factor (VEGF) receptors (sFlt-1 and sKDR) and pterins, alongside genetic variants in VEGF receptor genes, VEGFR-1 and VEGFR-2.
|
30111293 |
2018 |
|
Acute Lung Injury
|
0.200 |
Biomarker
|
disease |
RGD |
Time-dependent alterations of VEGF and its signaling molecules in acute lung injury in a rat model of sepsis.
|
21528367 |
2012 |
|
Acute lymphocytic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the present study, we identified a unique subpopulation of Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) cells coexpressing markers of endothelial cells (including VE-cadherin, PECAM-1, and Flk-1) and committed B-lineage progenitors.
|
17638851 |
2007 |
|
Acute lymphocytic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Umbilical cord blood‑derived Helios‑positive regulatory T cells promote angiogenesis in acute lymphoblastic leukemia in mice via CCL22 and the VEGFA‑VEGFR2 pathway.
|
30896872 |
2019 |
|
Acute lymphocytic leukemia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Sema3 and KDR genes expression levels displayed a significantly positive correlation in normal control and ALL nonadherent cells (r=0.703, P=0.002; r=0.999, P=0.001).
|
16085543 |
2005 |
|
Acute monocytic leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
AML with t(8;21) is the most dependent subtype on VEGF with both VEGFR1 and VEGFR2. t(15;17)AML cells depend on VEGF with VEGFR1.
|
19342098 |
2009 |
|
Acute monocytic leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our results provide evidence for increased expression of VEGF/VEGFR-2 of leukemic blasts and correlation with angiogenesis in the bone marrow of AML patients.
|
12094254 |
2002 |
|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared with the AMI group, BHD promoted the expression of Cav-1, VEGF, VEGFR2, and p-ERK in the infarction border zone after AMI.
|
31178960 |
2019 |
|
Acute pancreatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In Romanian cohort, we found an association between the KDR 604A→<i>G</i> polymorphism and acute pancreatitis and pancreatic cancer.
|
28218664 |
2017 |
|
Acute Undifferentiated Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consistent with an embryologically derived hemangioblast, the neoplastic cells demonstrated coexpression of the mesodermal markers brachyury, Flk-1 (vascular endothelial growth factor-2), and stem cell leukemia (Scl).
|
17298169 |
2007 |
|
Adenocarcinoma
|
0.380 |
GeneticVariation
|
group |
BEFREE |
No KDR mutations were detected in exons 7, 11, and 21 by PCR-based sequencing; however, two variant single nucleotide polymorphism genotypes were associated with favorable overall survival in adenocarcinoma patients.
|
21724587 |
2011 |
|
Adenocarcinoma
|
0.380 |
Biomarker
|
group |
CTD_human |
Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma.
|
21472143 |
2011 |
|
Adenocarcinoma
|
0.380 |
GeneticVariation
|
group |
BEFREE |
For adenocarcinoma, VEGFR-2-906 C>T (C/T vs. CC: HR, 0.19; 95% CI, 0.43-0.82; p=0.027) and VEGFR-2-271 G>A (G/A vs. G/G: HR, 0.25; 95% CI, 0.07-0.86; p=0.027) predicted longer time to local recurrence and VEGFR-2-906 C>T was a predictor for better OS (T/T vs. C/C: HR, 0.28; 95% CI, 0.09-0.84; p=0.024).
|
22395975 |
2012 |
|
Adenocarcinoma
|
0.380 |
Biomarker
|
group |
BEFREE |
CEUS with VEGFR2-targeted microbubbles allowed for monitoring regorafenib functional and molecular therapy effects on experimental colorectal adenocarcinomas with a significant decline of CEUS and DCE-MRI perfusion parameters as well as a significant reduction of specifically bound microbubbles under therapy, consistent with a reduced expression of VEGFR2.
|
28060884 |
2017 |
|
Adenocarcinoma
|
0.380 |
Biomarker
|
group |
BEFREE |
In this study, we aimed to assess the safety and preliminary antitumour activity of ramucirumab (an IgG1 VEGFR-2 antagonist) combined with pembrolizumab (an IgG4 PD-1 antagonist) in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, or urothelial carcinoma.
|
31301962 |
2019 |
|
Adenocarcinoma
|
0.380 |
Biomarker
|
group |
BEFREE |
Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma.
|
31733011 |
2019 |
|
Adenocarcinoma
|
0.380 |
AlteredExpression
|
group |
LHGDN |
Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma.
|
18609713 |
2008 |
|
Adenocarcinoma
|
0.380 |
Biomarker
|
group |
BEFREE |
Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma.
|
28501090 |
2017 |
|
Adenocarcinoma
|
0.380 |
Biomarker
|
group |
BEFREE |
We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
|
30718072 |
2019 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Subsequent logistic regression analysis indicated that 10 SNPs (rs2070744 of NOS3, rs720321 of BCL2, rs17757541 of BCL2, rs11775256 of TNFRSF10A, rs1035142 of CASP8, rs2236302 of MMP14, rs4740363 of ABL1, rs696217 of GHRL, rs2445762 of CYP19A1, and rs11941492 of VEGFR2/KDR) were significantly associated with early onset of EA (≤55 vs >55 years, all P < .05 after adjusting for co-variates and false discovery rate).
|
21472143 |
2011 |